Remove 2019 Remove Food and Drug Administration Remove Leads
article thumbnail

A perfect storm for biotech stocks

World of DTC Marketing

According to STAT News “after a double-digit decline in 2021, the sector has fallen another 20% in the new year, erasing billions in value and leading even the most seasoned investors to question whether biotech has further to fall. That’s significantly down from 2019, with 70 deals worth $261 billion. Bernie Sanders, I-Vt.,

article thumbnail

Disruption in healthcare is coming

World of DTC Marketing

Between 2019 and 2021, Alphabet’s venture-capital arms, Google Ventures, and Gradient Ventures, and its private-equity unit, CapitalG, made about 100 deals, a quarter of Alphabet’s combined total, in life sciences and health care. Google launched itself into the wearables business in 2019 with a $2.1bn acquisition of Fitbit.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. They relied so much on a new drug that they tried to market a product with bad science behind it. The pharma industry is a giant behemoth that needs new drugs to survive and grow.

Pharma 210
article thumbnail

Can Hepatitis C drugs reduce symptoms of PTSD?

European Pharmaceutical Review

The researchers studied 254 VA patients who were diagnosed with PTSD and hepatitis C between October 1999 and September 2019. PTSD is a potentially chronic condition that disrupts lives and can lead to or exacerbate existing health issues such as depression, anxiety, eating disorders, and suicidal thoughts.

article thumbnail

Early diagnosis in Alzheimer’s disease: A first step towards better care

Clarivate

As dementia becomes more severe, people require greater care, and develop complications such as pressure ulcers, infections, dysphagia, malnutrition and aspiration pneumonia – a leading cause of death among people with Alzheimer’s (Anon., Currently, of the eight drugs approved by the U.S. Food and Drug Administration, 2023 and 2024).

article thumbnail

SERB Pharmaceuticals acquires US rights for bentracimab from SFJ

Pharmaceutical Technology

SFJ Pharmaceuticals will lead the ongoing clinical trial of bentracimab. In partnership with SERB Pharmaceuticals, the company will also file a biologics licence application (BLA) to the US Food and Drug Administration (FDA) later this year. The US FDA granted breakthrough therapy designation to bentracimab in 2019.

article thumbnail

CARsgen and Huadong Medicine to commercialise CT053 in mainland China

Pharmaceutical Technology

In October last year, CARsgen submitted a new drug application (NDA) for CT053 to China’s National Medical Products Administration (NMPA). The US Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations to the company’s zevor-cel in 2019.

Medicine 119